Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisia vulgaris, commonly known as mugwort, is a perennial weed whose various extracts and components are extensively studied for their diverse biological activities. It is a significant source of allergenic pollen, containing proteins such as Art v 1, Art v 2, Art v 3, Art v 4, Art v 5, and Art v 6, which are responsible for respiratory allergies. Extracts from Artemisia vulgaris have demonstrated potent antimicrobial activity against various bacteria (including *Bacillus cereus*, *S. aureus*, MRSA, *E. coli*) and fungi, as well as strong antioxidant properties. Research also indicates its potential in inhibiting cancer cell transformation and its efficacy as an acaricidal and repellent agent against pests like *Aceria pongamiae Keifer*. Furthermore, phytocompounds from Artemisia vulgaris have been investigated for their ability to inhibit the NF-κB pathway, and an essential oil blend containing it has shown to activate the AMPK/Nrf2/HO-1 signaling pathway, suggesting protective effects against oxidative stress injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Artemisia vulgaris.